Multidisciplinary Expert Insights: Assessing Hereditary Cancer Risks for Genomic Tumor Testing

Genomic tumor testing performed for treatment decision-making may also identify variants associated with hereditary cancer risk. However, interpreting possible hereditary or germline risks based on genomic tumor testing can be challenging. In this educational webinar, a multidisciplinary panel of clinical and laboratory experts discusses a case that highlights factors relevant for the interpretation of tumor results for hereditary risks.
 
The Jackson Laboratory is a non-profit biomedical research organization and National Cancer Institute-designated Cancer Center.

Panelists

Kate Reed, M.P.H., Sc.M., CGC, Director, Precision Oncology Education, The Jackson Laboratory

Nick Renzette, Ph.D., Supervision, Clinical Data Analysis & Reporting, The Jackson Laboratory

Stephanie Sharp, M.S., CGC, Genetic Counselor, Cancer Risk and Prevention Clinic, Maine Medical Center

Christine Walko, Pharm.D., BCOP, FCCP, Associate Member, Individualized Cancer Management, Moffitt Cancer Center